U.S. Meniere's Disease Drug Market - Industry Trends and Forecast To 2027
Short Description
U.S. Meniere’s Disease Drug Market By Type (Classic, Bilateral, Vestibular), Treatment (Off Label Drugs, Novel Therapeutics), Drug Type (Generics, Branded), Route of Administration (Oral, Parenteral), End Users (Homecare, Hospitals, Specialty Clinics, Academic and Research Institute), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies), Country (U.S.)
Market Definition:
Meniere's disease is a middle ear disorder occurs in inner ear which could leads to vertigo, ear ringing (tinnitus), ear pain and hearing problems. Meniere's disease mostly occur in one ear in most instances. Meniere's disease could affect anyone and everyone, but mostly occur in people aged between 20 to 50 years. Abnormal immune response, Allergies, genetic predisposition, viral infection, migraines, head trauma is some of the major causes of Meniere's disease. Meniere's disease is a chronic condition which might results into permanent loss of hearing, but proper treatment might help control the symptoms.
Market Segmentation:
U.S. meniere’s disease drug market is categorized into six notable segments which are based on the basis of type, treatment, drug type, route of administration, end user and distribution channel.
On the basis of type, the market is segmented into classic, vestibular and bilateral.
On the basis of treatment, the market is segmented into off label drugs and novel therapeutics.
On the basis of drug type, the market is segmented into branded and generics.
On the basis of route of administration, the market is segmented into oral and parenteral.
On the basis of end user, the market is segmented into hospitals, specialty clinics, homecare and academic and research institute.
On the basis of distribution channel, the market is segmented into hospital pharmacy, online pharmacy and retail pharmacy.
Market Players
The key market players for U.S. meniere’s disease drug market are listed below:
• Hikma Pharmaceuticals PLC
• Mylan N.V.
• Pfizer Inc.
• Fresenius Kabi AG
• Baxter
• F. Hoffmann-La Roche Ltd
• Bausch Health
• Akorn, Incorporated
• Amneal Pharmaceuticals LLC
• Sound Pharmaceuticals
• Orbis Biosciences, Inc.
• Otonomy, Inc.
• Quark
• Otologic Pharmaceutics
• Auris Medical,
The single user license is non-downloadable and non-printable. Global Site license allows these actions.
- 1 Introduction
- 1.1 Objectives Of The Study
- 1.2 Market Definition
- 1.3 Overview Of U.S. Meniere’s Disease Drug Market
- 1.4 Limitations
- 1.5 Markets Covered
- 2 Market Segmentation
- 2.1 Markets Covered
- 2.2 Geographical Scope
- 2.3 Years Considered For The Study
- 2.4 Currency And Pricing
- 2.5 Dbmr Tripod Data Validation Model
- 2.6 Multivariate Modelling
- 2.7 Products Lifeline Curve
- 2.8 Primary Interviews With Key Opinion Leaders
- 2.9 Dbmr Market Position Grid
- 2.10 Vendor Share Analysis
- 2.11 Secondary Sources
- 2.12 Assumptions
- 3 Executive Summary
- 4 Premium Insights
- 5 Epidemiology
- 6 Market Overview
- 6.1 Drivers
- 6.1.1 Increasing Prevalnce Of Meniere’s Disease
- 6.1.2 Increasing Awareness About Diagnosis And Treatment Of The Disease
- 6.2 Restraints
- 6.2.1 Unmet Medical Needs
- 6.2.2 Rigorous Regulations Protocols
- 6.3 Opportunities
- 6.3.1 Increasing Research Activities For Meniere’s Disease
- 6.3.2 Rising Grants In The Research & Development For Drug Development
- 6.3.3 Lack Of Approved Drug
- 6.4 Challenges
- 6.4.1 Low Interest Of Pharmaceutical Companies Towards Orphan Drug Development
- 6.4.2 Availability Of Alternative Medicines, Devices And Surgeries
- 6.4.3 Challenging Diagnosis And Treatment
- 7 U.S. Meniere’s Disease Drug Market, By Type
- 7.1 Overview
- 7.2 Classic
- 7.3 Bilateral
- 7.4 Vestibular
- 8 U.S. Meniere’s Disease Drug Market, By Treatment
- 8.1 Overview
- 8.2 Off Label Drugs
- 8.2.1 Tranquillizers
- 8.2.1.1 Diazepam
- 8.2.1.2 Lorazepam
- 8.2.1.3 Others
- 8.2.2 Antihistaminic Agents
- 8.2.2.1 Betahistine
- 8.2.2.2 Promethazine
- 8.2.2.3 Dimenhydrinate
- 8.2.2.4 Meclizine Hydrochloride
- 8.2.2.5 Others
- 8.2.3 Diuretic Agents
- 8.2.3.1 Hydrochlorothiazide
- 8.2.3.2 Acetazolamide
- 8.2.3.3 Triamterene
- 8.2.3.4 Others
- 8.2.4 Antibiotic Agents
- 8.2.4.1 Gentamicin
- 8.2.4.2 Streptomycin
- 8.2.4.3 Others
- 8.2.5 Corticosteroids
- 8.2.5.1 Prednisone
- 8.2.5.2 Dexamethasone
- 8.2.5.3 Others
- 8.2.6 Others
- 8.3 Novel Therapeutics
- 9 U.S. Meniere’s Disease Drug Market, By Drug Type
- 9.1 Overview
- 9.2 Generics
- 9.3 Branded
- 10 U.S. Meniere’s Disease Drug Market, By Route Of Administration
- 10.1 Overview
- 10.2 Oral
- 10.3 Parenteral
- 11 U.S. Meniere’s Disease Drug Market, By End User
- 11.1 Overview
- 11.2 Homecare
- 11.3 Hospitals
- 11.4 Specialty Clinics
- 11.5 Academic And Research Institute
- 12 U.S. Meniere’s Disease Drug Market, By Distribution Channel
- 12.1 Overview
- 12.2 Retail Pharmacies
- 12.3 Hospital Pharmacies
- 12.4 Online Pharmacies
- 13 U.S. Meniere’s Disease Drug Market, Company Landscape
- 14 Company Profile
- 14.1 Pfizer Inc.
- 14.1.1 Company Snapshot
- 14.1.2 Revenue Analysis
- 14.1.3 Product Portfolio
- 14.1.4 Recent Development
- 14.2 Mylan N.V.
- 14.2.1 Company Snapshot
- 14.2.2 Revenue Analysis
- 14.2.3 Product Portfolio
- 14.2.4 Recent Development
- 14.3 Bausch Health
- 14.3.1 Company Snapshot
- 14.3.2 Revenue Analysis
- 14.3.3 Product Portfolio
- 14.3.4 Recent Development
- 14.4 Akorn, Incorporated
- 14.4.1 Company Snapshot
- 14.4.2 Revenue Analysis
- 14.4.3 Product Portfolio
- 14.4.4 Recent Development
- 14.5 Amneal Pharmaceuticals Llc
- 14.5.1 Company Snapshot
- 14.5.2 Revenue Analysis
- 14.5.3 Product Portfolio
- 14.5.4 Recent Development
- 14.6 Baxter
- 14.6.1 Company Snapshot
- 14.6.2 Revenue Analysis
- 14.6.3 Product Portfolio
- 14.6.4 Recent Development
- 14.7 F. Hoffmann-la Roche Ltd
- 14.7.1 Company Snapshot
- 14.7.2 Revenue Analysis
- 14.7.3 Product Portfolio
- 14.7.4 Recent Development
- 14.8 Fresenius Kabi Ag
- 14.8.1 Company Snapshot
- 14.8.2 Revenue Analysis
- 14.8.3 Product Portfolio
- 14.8.4 Recent Development
- 14.9 Hikma Pharmaceuticals Plc
- 14.9.1 Company Snapshot
- 14.9.2 Revenue Analysis
- 14.9.3 Product Portfolio
- 14.9.4 Recent Development
- 15 Pipeline Company Profile
- 15.1 Auris Medical
- 15.1.1 Company Snapshot
- 15.1.2 Revenue Analysis
- 15.1.3 Pipeline Portfolio
- 15.2 Orbis Biosciences, Inc.
- 15.2.1 Company Snapshot
- 15.2.2 Pipeline Portfolio
- 15.3 Otologic Pharmaceutics
- 15.3.1 Company Snapshot
- 15.3.2 Pipeline Portfolio
- 15.4 Otonomy, Inc.
- 15.4.1 Company Snapshot
- 15.4.2 Revenue Analysis
- 15.4.3 Pipeline Portfolio
- 15.5 Quark
- 15.5.1 Company Snapshot
- 15.5.2 Pipeline Portfolio
- 15.6 Sound Pharmaceuticals
- 15.6.1 Company Snapshot
- 15.6.2 Pipeline Portfolio
- 16 Questionnaire
- 17 Related Reports